Powder: -20°C for 3 years | In solvent: -80°C for 2 years
TJ-M2010-5 是一种 MyD88 抑制剂,可与 TIR 结构域结合以干扰其同源二聚化并抑制 MyD88 信号传导。 TJ-M2010-5 可用于心肌缺血/再灌注损伤研究。
产品描述 | TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain to interfere with its homodimerization and suppress MyD88 signaling. TJ-M2010-5 can be used in myocardial ischemia/reperfusion injury studies. |
体外活性 | TJ-M2010-5 (0 μM, 5 μM, 10 μM, 20 μM and 30 μM) prevents B cell proliferation and induces B cells apoptosis after stimulation with R848 (500 ng/mL)[1]. |
体内活性 | TJ-M2010-5 statistically significantly decreases TNF-α, IL-6, G-CSF, MIP-1β, IL-11, IL-17A, IL-22, and IL-23 serum concentrations in mice at both two and seven weeks postinduction. In a 10-week CAC mouse model, TJ-M2010-5 statistically significantly reduces AOM/DSS-induced colitis and completely prevented CAC development with less related body mass loss, results in 0% mortality of treated mice, decreases cell proliferation, and increased apoptosis in colon tissue[2]. |
分子量 | 406.54 |
分子式 | C23H26N4OS |
CAS No. | 1357471-57-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
DMSO: 95 mg/mL (233.68 mM), Need ultrasonic
( < 1 mg/mL refers to the product slightly soluble or insoluble )
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
bottom
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TJ-M2010-5 1357471-57-8 Immunology/Inflammation MyD88 ischemia MIRI Anoxia factor injury reoxygenation inhibit reperfusion differentiation Inhibitor remodeling myocardial MyD88,TLR TJ-M-2010-5 myeloid TJM20105 TJ M2010 5 inhibitor